Welcome to another episode of The Future of Business. Today, we dive into how artificial intelligence is actively breaking down the barriers of a slow-moving medical system. I am joined by Andy Moye, a former Navy pilot with a PhD in health economics who previously led Page to secure the first-ever FDA approval for AI in cancer pathology. Now serving as the CEO of GlidePath Health, Andy is building AI platforms to untangle the complex logistics behind advanced cell and gene therapies. We discuss the alarming 14-year technology adoption lag in healthcare, the devastating impact of administrative waste, and how AI orchestration will drastically shorten the time it takes for patients to receive life-saving treatments.
Key Takeaways
Cancer diagnosis still relies heavily on manual pathology methods that have remained fundamentally unchanged since the mid-1800s.
The healthcare industry suffers from a massive adoption lag, where cutting-edge technology often takes up to 14 years to become standard practice.
System backlogs have historically forced patients to wait 40 to 50 days just to receive a critical cancer diagnosis.
Groundbreaking, curative cell and gene therapies like CRISPR and CAR T are severely bottlenecked by manual scheduling processes, spreadsheets, and phone calls.
GlidePath Health is developing an enterprise AI orchestration platform to fully automate these logistical workflows, ensuring patients are treated faster to improve outcomes.
Deploying AI in healthcare requires immense trust, rigorous data protection, cybersecurity compliance, and 99.9999% system uptime to ensure patient safety.
Links & Resources
Guest Website: AndyMoye.com
Book:From Bunker Hill to the Boardroom: Battle Tested Leadership for Today's Executives by Andy Moye
Podden och tillhörande omslagsbild på den här sidan tillhör
Jay Dhillon. Innehållet i podden är skapat av Jay Dhillon och inte av,
eller tillsammans med, Poddtoppen.
